Pharma shares in focus; Lupin, Sun Pharma, Aurobindo up over 3%

The S&P BSE Healthcare index was up 2.4% as compared to 1.5% rise in the S&P BSE Sensex at 02:55 pm

Zydus acquires derma brand Melgain from Issar Pharma
SI Reporter Mumbai
Last Updated : Nov 25 2016 | 3:08 PM IST
Shares of pharmaceuticals companies were in focus and gained up to 9% on the BSE in intra-day trade following the recent sharp slide of the rupee against the dollar.

Lupin, Sun Pharmaceutical Industries, Aurobindo Pharma, Cipla, Cadila Healthcare, Shilpa Medicare and Dr Reddys Laboratories were up 2% to 8% on the BSE.

At 02:55 pm, the S&P BSE Healthcare index, the second largest gainer among sectoral indices after IT index, was up 2.4% as compared to 1.5% rise in the S&P BSE Sensex.

Weakness in rupee could boost sales of pharma companies in rupee terms as pharma firms derive substantial revenue from exports.

On Thursday, the rupee closed at 68.73 to a dollar after touching 68.865, in intra-day trades, a record low of August 28, 2013.

Among the individual stocks, Sun Pharma was up 4.5% to Rs 715 on BSE in intra-day trade.  Since November 8, it rallied 12.6% as compared to 4.8% decline in the benchmark index.

The company on Wednesday announced the acquisition of 85.1% equity stake in JSC Biosintez – a Russian pharmaceutical company with operations in Russia and the CIS region – for a consideration of USD 24 million.

Analysts at Motilal Oswal Securities maintain ‘buy’ rating on the stock with a target price of Rs 925.

“We believe the current stock price does not reflect key positives like Ranbaxy integration benefits, Halol and Mohali plant resolution, and investments in the specialty business. We see the current weakness in stock price as an opportunity to add. Sun Pharma remains an attractive Indian play on specialty business in the US,” the brokerage house said in recent report.

Shilpa Medicare has surged 9% to Rs 626 after the company reported 64% year on year growth in net profit at Rs 38.24 crore for the quarter ended September 30, 2016 (Q2FY17). It had profit of Rs 23.33 crore in the same period last year.

COMPANY LATEST PREV CLOSE GAIN(%)
LYKA LABS 61.40 51.20 19.92
SHILPA MEDICARE 624.50 572.30 9.12
ORCHID PHARMA 27.05 25.15 7.55
MANGALAM DRUGS 142.65 135.25 5.47
GRANULES INDIA 108.95 104.00 4.76
ALEMBIC 34.70 33.15 4.68
LINCOLN PHARMA. 192.80 184.25 4.64
AUROBINDO PHARMA 742.05 710.95 4.37
J B CHEM & PHARM 351.45 337.40 4.16
SUN PHARMA.INDS. 711.40 683.60 4.07
RPG LIFESCIENCE. 447.55 430.10 4.06
GUFIC BIOSCIENCE 47.50 45.70 3.94
SMS PHARMA. 92.30 88.85 3.88
FORTIS HEALTH. 176.90 170.35 3.85
CAPLIN POINT LAB 360.80 348.00 3.68
VIVIMED LABS. 88.90 85.75 3.67
LUPIN 1512.30 1460.30 3.56
NECTAR LIFESCI. 31.70 30.65 3.43
CADILA HEALTH. 409.70 396.45 3.34
CLARIS LIFESCIEN 276.95 268.50 3.15

 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 25 2016 | 2:53 PM IST

Next Story